Danish biotech leader Genmab has announced an $8 billion all-cash acquisition of Merus, a clinical-stage bispecific antibody specialist well-known for petosemtamab, its lead EGFRxLGR5 bispecific promising for head and neck cancer. The deal, unanimously approved by both boards, represents a transformational growth opportunity, allowing Genmab to expand and diversify its oncology portfolio as it transitions to a wholly owned development model. Petosemtamab has received two breakthrough therapy designations, underscoring its clinical potential. This acquisition marks a significant milestone in developing next-generation bispecific therapeutics for oncology.